Stem Cell-based Therapeutic Strategies for Cartilage Defects and Osteoarthritis

Research output: Contribution to journalReview article

12 Citations (Scopus)
9 Downloads (Pure)

Abstract

The gold standard cell therapy for repair of articular cartilage defects is autologous chondrocyte implantation, with good outcomes long-term. Mesenchymal stromal/stem cells (MSCs) from bone marrow or connective tissues such as fat are being pursued as alternatives for cartilage repair, and are trialled via intra-articular administration in patients with knee osteoarthritis. Early-phase clinical studies concur on safety and provide some promising insight into efficacy, but the mechanism of action remains unclear. Recent studies implicate extracellular vesicles as important mediators of MSC action, offering exciting therapeutic prospects. Our increasing understanding of the mechanisms underlying intrinsic articular cartilage maintenance and repair fosters hope that novel/repurposed therapeutics could elicit repair through activation of endogenous stem/progenitor cells to maintain healthy joints and prevent osteoarthritis
Original languageEnglish
Pages (from-to)74-80
Number of pages7
JournalCurrent Opinion in Pharmacology
Volume40
Early online date3 Apr 2018
DOIs
Publication statusPublished - Jun 2018

Fingerprint

Mesenchymal Stromal Cells
Osteoarthritis
Cartilage
Stem Cells
Articular Cartilage
Joints
Knee Osteoarthritis
Therapeutics
Chondrocytes
Cell- and Tissue-Based Therapy
Connective Tissue
Bone Marrow
Fats
Maintenance
Safety
Bone and Bones

Keywords

  • Cartilage
  • Osteoarthritis
  • Cell therapy
  • Mesenchymal stem cell
  • Chondrocyte

Cite this

Stem Cell-based Therapeutic Strategies for Cartilage Defects and Osteoarthritis. / de Bari, Cosimo; Roelofs, Anke J.

In: Current Opinion in Pharmacology, Vol. 40, 06.2018, p. 74-80.

Research output: Contribution to journalReview article

@article{a6697f8c4f04450d8322a370883ae07e,
title = "Stem Cell-based Therapeutic Strategies for Cartilage Defects and Osteoarthritis",
abstract = "The gold standard cell therapy for repair of articular cartilage defects is autologous chondrocyte implantation, with good outcomes long-term. Mesenchymal stromal/stem cells (MSCs) from bone marrow or connective tissues such as fat are being pursued as alternatives for cartilage repair, and are trialled via intra-articular administration in patients with knee osteoarthritis. Early-phase clinical studies concur on safety and provide some promising insight into efficacy, but the mechanism of action remains unclear. Recent studies implicate extracellular vesicles as important mediators of MSC action, offering exciting therapeutic prospects. Our increasing understanding of the mechanisms underlying intrinsic articular cartilage maintenance and repair fosters hope that novel/repurposed therapeutics could elicit repair through activation of endogenous stem/progenitor cells to maintain healthy joints and prevent osteoarthritis",
keywords = "Cartilage, Osteoarthritis, Cell therapy, Mesenchymal stem cell, Chondrocyte",
author = "{de Bari}, Cosimo and Roelofs, {Anke J.}",
note = "We are grateful to Medical Illustration at the University of Aberdeen for drawing the schematic in Figure 1, and to Arthritis Research UK (grants 19667, 20050, 20775, 20865, 21156) and the Medical Research Council (grants MR/L020211/1, MR/L022893/1) for supporting our work.",
year = "2018",
month = "6",
doi = "10.1016/j.coph.2018.03.009",
language = "English",
volume = "40",
pages = "74--80",
journal = "Current Opinion in Pharmacology",
issn = "1471-4892",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Stem Cell-based Therapeutic Strategies for Cartilage Defects and Osteoarthritis

AU - de Bari, Cosimo

AU - Roelofs, Anke J.

N1 - We are grateful to Medical Illustration at the University of Aberdeen for drawing the schematic in Figure 1, and to Arthritis Research UK (grants 19667, 20050, 20775, 20865, 21156) and the Medical Research Council (grants MR/L020211/1, MR/L022893/1) for supporting our work.

PY - 2018/6

Y1 - 2018/6

N2 - The gold standard cell therapy for repair of articular cartilage defects is autologous chondrocyte implantation, with good outcomes long-term. Mesenchymal stromal/stem cells (MSCs) from bone marrow or connective tissues such as fat are being pursued as alternatives for cartilage repair, and are trialled via intra-articular administration in patients with knee osteoarthritis. Early-phase clinical studies concur on safety and provide some promising insight into efficacy, but the mechanism of action remains unclear. Recent studies implicate extracellular vesicles as important mediators of MSC action, offering exciting therapeutic prospects. Our increasing understanding of the mechanisms underlying intrinsic articular cartilage maintenance and repair fosters hope that novel/repurposed therapeutics could elicit repair through activation of endogenous stem/progenitor cells to maintain healthy joints and prevent osteoarthritis

AB - The gold standard cell therapy for repair of articular cartilage defects is autologous chondrocyte implantation, with good outcomes long-term. Mesenchymal stromal/stem cells (MSCs) from bone marrow or connective tissues such as fat are being pursued as alternatives for cartilage repair, and are trialled via intra-articular administration in patients with knee osteoarthritis. Early-phase clinical studies concur on safety and provide some promising insight into efficacy, but the mechanism of action remains unclear. Recent studies implicate extracellular vesicles as important mediators of MSC action, offering exciting therapeutic prospects. Our increasing understanding of the mechanisms underlying intrinsic articular cartilage maintenance and repair fosters hope that novel/repurposed therapeutics could elicit repair through activation of endogenous stem/progenitor cells to maintain healthy joints and prevent osteoarthritis

KW - Cartilage

KW - Osteoarthritis

KW - Cell therapy

KW - Mesenchymal stem cell

KW - Chondrocyte

U2 - 10.1016/j.coph.2018.03.009

DO - 10.1016/j.coph.2018.03.009

M3 - Review article

VL - 40

SP - 74

EP - 80

JO - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

SN - 1471-4892

ER -